Wuhan hengheda Pharm offers high quality 4-O-Methylhonokiol, 4-O-Methylhonokiol is a naturally occurring lignan derived primarily from the bark and seeds of Magnolia officinalis and related species, which have been utilized in traditional medicine for centuries. Chemically, it is a methylated derivative of honokiol, characterized by the addition of a methoxy group (-OCH?) at the 4-position of the biphenyl core structure. This modification enhances its lipophilic properties, potentially improving membrane permeability and bioavailability compared to its parent compound. With a molecular formula of C??H??O? and a molecular weight of 316.4 g/mol, 4-O-methylhonokiol exhibits structural similarities to other magnolia-derived bioactive compounds, such as honokiol and magnolol, yet demonstrates distinct pharmacological profiles due to its unique substitution pattern.
Extensive preclinical studies have highlighted 4-O-methylhonokiol’s multifaceted biological activities. It exhibits potent anti-inflammatory and antioxidant effects, primarily through the inhibition of NF-κB and MAPK signaling pathways, making it a candidate for treating chronic inflammatory conditions, including neurodegenerative diseases and metabolic disorders. Furthermore, its anxiolytic and neuroprotective properties—mediated via modulation of GABAergic systems and activation of Nrf2-mediated antioxidant responses—suggest therapeutic potential for anxiety, depression, and Alzheimer’s disease. Emerging evidence also points to anti-cancer activity, where it induces apoptosis and suppresses metastasis in various cancer cell lines by targeting PI3K/AKT and Wnt/β-catenin pathways. Additionally, its ability to improve insulin sensitivity and mitigate oxidative stress in metabolic models underscores its relevance in addressing obesity-linked complications. Despite promising preclinical data, further research is required to evaluate its pharmacokinetics, safety profile, and efficacy in clinical settings, paving the way for potential pharmaceutical or nutraceutical applications.
關(guān)鍵字： 厚樸;厚樸酚;和厚樸酚;
武漢恒和達生物醫(yī)藥有限公司成立于2013年，湖北省高新技術(shù)企業(yè)，主要從事原料藥、高端醫(yī)藥中間體、分子砌塊的研發(fā)與生產(chǎn)，恒和達生物經(jīng)過多年拼搏，憑借產(chǎn)品的優(yōu)良質(zhì)量以及自身優(yōu)異的合成和供應(yīng)能力，獲得業(yè)界廣泛認(rèn)可。